The effect of 'goal directed' fluid management during gynaecological oncology surgery using the oesophageal Doppler probe

Submission date	Recruitment status	[X] Prospectively registered
23/05/2010	No longer recruiting	[_] Protocol
Registration date	Overall study status	[] Statistical analysis plan
04/08/2010	Completed	[_] Results
Last Edited 04/10/2017	Condition category Surgery	Individual participant data
		[] Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s) Scientific

Contact name Miss Khadra Galaal

Contact details

Northern Gynaecological Oncology Centre Queen Elizabeth Hospital Sheriff Hill Gateshead United Kingdom NE9 6SX +44 (0)191 445 2597 khadra.galaal@ghnt.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

The effect of intra-operative fluid optimisation using the oesophageal Doppler monitor in gynaecological oncology surgery

Study objectives

Goal directed optimisation of intra-operative haemodynamics using oesophageal Doppler monitoring reduces length of hospital stay and improves outcome.

Ethics approval required Old ethics approval format

Ethics approval(s) Not provided at time of registration

Study design Single-centre interventional prospective double-blinded randomised controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Gynaecological oncology surgery

Interventions

Two groups: control and protocol group.

Both groups will have DP6 Doppler probe (product code 9070-7001) inserted at the time of intubation. All patients will have standard pre-operative, intra-operative and post-operative care. Fluids (crystalloid, colloid and blood/blood products) will be given at the discretion of the anaesthetist, guided by standard haemodynamic monitoring and operative losses.

Only the protocol group will have direct measurement of central vascular flow using CardioQ-ODM monitor (product code 9051-7056) including corrected flow time (FTc), stroke volume (SV),

N/A

stroke distance (SD) and peak velocity (PV) and small colloid (fluid) challenges to maintain FTc greater than 0.35 seconds and optimise SV.

The intervention will last until the end of the operation and the probe will be removed at the time of extubation.

Intervention Type Procedure/Surgery

Phase Not Applicable

Primary outcome measure

The aim of this study is to compare the effect of a target driven intra-operative intravenous fluid management using oesophageal Doppler to a standard fluid regimen on complication rate after surgery for corpus uteri, ovarian and cervical cancer. Measured until 5th post-operative day.

Secondary outcome measures

To evaluate the effect of target driven intra-operative fluid management using oesophageal Doppler on hospital stay, measured on day of discharge.

Overall study start date 01/11/2010

Completion date 01/05/2012

Eligibility

Key inclusion criteria

1. Patients aged 20 - 85 years, female

2. Recruited from the Queen Elizabeth Hospital, Gateshead

3. Written informed consent

4. Undergoing elective major gynaecological oncology surgery for ovarian, endometrial and cervical carcinoma

Participant type(s)

Patient

Age group Adult

Sex

Female

Target number of participants 70 patients in each group (140 in total)

Key exclusion criteria

Contraindication to oesophageal Doppler use:

- 1. Oesophageal surgery or stent
- 2. Oesophageal stricture
- 3. Oesophageal varices
- 4. Pharyngeal pouch
- 5. Moderate/severe aortic valve disease
- 6. Patient refusal

Date of first enrolment 01/11/2010

Date of final enrolment 01/05/2012

Locations

Countries of recruitment England

United Kingdom

Study participating centre Queen Elizabeth Hospital Gateshead United Kingdom NE9 6SX

Sponsor information

Organisation Gateshead Health NHS Foundation Trust (UK)

Sponsor details c/o Mrs Alison Harvey Research and Development Queen Elizabeth Hospital Sheriff Hill Gateshead England United Kingdom NE9 6SX +44 (0)191 445 2155 alison.harvey@ghnt.nhs.uk

Sponsor type

Hospital/treatment centre

Website http://www.gatesheadhealth.nhs.uk/index.php

ROR https://ror.org/01aye5y64

Funder(s)

Funder type Hospital/treatment centre

Funder Name Northern Gynaecological Oncology Centre (UK)

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Not provided at time of registration